X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NOVARTIS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NOVARTIS DIVIS LABORATORIES/
NOVARTIS
 
P/E (TTM) x 30.0 364.8 8.2% View Chart
P/BV x 5.2 18.0 28.9% View Chart
Dividend Yield % 1.0 1.6 59.3%  

Financials

 DIVIS LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
NOVARTIS
Mar-16
DIVIS LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,222982 124.4%   
Low Rs784556 141.0%   
Sales per share (Unadj.) Rs153.1252.9 60.5%  
Earnings per share (Unadj.) Rs39.962.1 64.3%  
Cash flow per share (Unadj.) Rs44.663.3 70.5%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.01.3 76.7%  
Book value per share (Unadj.) Rs201.8363.6 55.5%  
Shares outstanding (eoy) m265.4731.96 830.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.63.0 215.4%   
Avg P/E ratio x25.112.4 202.9%  
P/CF ratio (eoy) x22.512.2 185.1%  
Price / Book Value ratio x5.02.1 235.0%  
Dividend payout %25.016.1 155.6%   
Avg Mkt Cap Rs m266,26624,580 1,083.2%   
No. of employees `0009.70.8 1,294.5%   
Total wages/salary Rs m4,6871,801 260.2%   
Avg. sales/employee Rs Th4,175.010,748.9 38.8%   
Avg. wages/employee Rs Th481.52,395.2 20.1%   
Avg. net profit/employee Rs Th1,089.32,641.1 41.2%   
INCOME DATA
Net Sales Rs m40,6438,083 502.8%  
Other income Rs m749829 90.3%   
Total revenues Rs m41,3928,913 464.4%   
Gross profit Rs m14,460234 6,174.4%  
Depreciation Rs m1,23337 3,360.5%   
Interest Rs m232 1,255.6%   
Profit before tax Rs m13,9531,025 1,361.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m3,349752 445.4%   
Profit after tax Rs m10,6041,986 533.9%  
Gross profit margin %35.62.9 1,228.0%  
Effective tax rate %24.073.4 32.7%   
Net profit margin %26.124.6 106.2%  
BALANCE SHEET DATA
Current assets Rs m40,10512,678 316.3%   
Current liabilities Rs m6,5952,433 271.0%   
Net working cap to sales %82.5126.7 65.1%  
Current ratio x6.15.2 116.7%  
Inventory Days Days11933 362.6%  
Debtors Days Days8122 358.8%  
Net fixed assets Rs m19,99569 28,894.5%   
Share capital Rs m531160 332.2%   
"Free" reserves Rs m53,04311,460 462.9%   
Net worth Rs m53,57411,621 461.0%   
Long term debt Rs m00-   
Total assets Rs m61,58514,400 427.7%  
Interest coverage x618.4570.5 108.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.6 117.6%   
Return on assets %17.313.8 125.0%  
Return on equity %19.817.1 115.8%  
Return on capital %26.123.6 110.6%  
Exports to sales %00.7 0.0%   
Imports to sales %25.218.6 135.8%   
Exports (fob) Rs mNA60 0.0%   
Imports (cif) Rs m10,2591,503 682.7%   
Fx inflow Rs m35,384186 18,992.9%   
Fx outflow Rs m10,3991,821 571.1%   
Net fx Rs m24,985-1,635 -1,528.6%   
CASH FLOW
From Operations Rs m11,4932,531 454.1%  
From Investments Rs m-11,372-8,270 137.5%  
From Financial Activity Rs m-93-386 24.1%  
Net Cashflow Rs m28-6,125 -0.5%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 2.0 590.0%  
FIIs % 19.0 1.6 1,187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.5 80.0%  
Shareholders   31,796 41,647 76.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 16, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS